Table 1.
Clinico-pathological characteristics of 315 pancreatic cancer patients stratified by I-score (high vs. low).
| Characteristic | Total | I-Score | p-Value | ||
|---|---|---|---|---|---|
| (n = 315) | Low (n = 239) | High (n = 76) | |||
| Age | Mean ± SD | 65.4 ± 9.7 | 65.8 ± 9.6 | 64.1 ± 10 | 0.1862 |
| Sex | |||||
| Male | 181 (57.5%) | 136 (75.1%) | 45 (24.9%) | 0.7231 | |
| Female | 134 (42.5%) | 103 (76.9%) | 31 (23.1%) | ||
| Status | |||||
| Resectable | 110 (34.9%) | 104 (94.5%) | 6 (5.5%) | <0.0001 | |
| Locally advanced | 78 (24.8%) | 74 (94.9%) | 4 (5.1%) | ||
| Metastatic | 127 (40.3%) | 61 (48.0%) | 66 (52.0%) | ||
| Pancreatic tumor location | |||||
| Body or tail | 164 (52.1%) | 108 (65.9%) | 56 (34.1%) | <0.0001 | |
| Head or neck | 151 (47.9%) | 131 (86.8%) | 20 (13.2%) | ||
| CA19-9, U/mL a | |||||
| ≤37 | 106 (34.1%) | 95 (98.6%) | 11 (10.4%) | <0.0001 | |
| >37 | 205 (65.9%) | 141 (68.8%) | 64 (31.2%) | ||
| CEA, U/mL b | |||||
| ≤5 | 152 (53.3%) | 138 (90.8%) | 14 (9.2%) | <0.0001 | |
| >5 | 133 (46.7%) | 77 (57.9%) | 56 (42.1%) | ||
| ECOG | |||||
| 0 + 1 | 309 (98.1%) | 234 (75.7%) | 75 (24.3%) | >0.9999 | |
| 2 + 3 | 6 (1.9%) | 5 (83.3%) | 1 (16.7%) | ||
Missing value a = 4, b = 30. Standard deviation, SD; carbohydrate antigen 19-9, CA19-9; carcinoembryonic antigen, CEA; Eastern Cooperative Oncology Group, ECOG.